Coronavirus disease 2019 vaccine: An overview of the progression and current use.
Clinical phases
clinical trials
coronavirus disease 2019
severe acute respiratory syndrome coronavirus 2
vaccine
Journal
Northern clinics of Istanbul
ISSN: 2536-4553
Titre abrégé: North Clin Istanb
Pays: Turkey
ID NLM: 101684520
Informations de publication
Date de publication:
2021
2021
Historique:
received:
26
05
2021
accepted:
17
08
2021
entrez:
15
12
2021
pubmed:
16
12
2021
medline:
16
12
2021
Statut:
epublish
Résumé
On December 31, 2019; unidentified pneumonia cases were reported from China. It was soon announced that these cases were of viral origin and the cause was a new coronavirus (CoV). Initially, the virus was called "novel CoV " and then defined as "severe acute respiratory syndrome CoV 2 (SARS-CoV-2)" after more detailed investigations. The disease caused by SARS-CoV-2 was named CoV disease 2019 (COVID-19) by the World Health Organization. The rapid spread of the disease in a few months has resulted in a global pandemic and it continues. However, there are no specific effective anti-viral drugs for SARS-CoV-2 infection, some antiviral drugs are using in the therapy of COVID-19 with limited success. Currently, for the prevention of the pandemic, global vaccination seems to be important. Antiviral protection of vaccines is provided by the development of antibodies that can neutralize the virus. Antibody response develops against spike protein and nucleocapsid protein but neutralizing antibodies are formed against the receptor-binding domain of the spike protein. It has also been shown that most viral proteins are recognized in T-cell responses. Vaccine discovery trials for COVID-19 have begun all over the world since the outbreak began. More than 100 vaccine studies against COVID-19 have been published in the last year. Some of them were urgently approved and used worldwide. The current study aimed to review the progression and current use of COVID-19 vaccines.
Identifiants
pubmed: 34909595
doi: 10.14744/nci.2021.99075
pii: NCI-8-529
pmc: PMC8630730
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
529-536Informations de copyright
Copyright: © 2021 by Istanbul Northern Anatolian Association of Public Hospitals.
Déclaration de conflit d'intérêts
Conflict of Interest: No conflict of interest was declared by the authors.
Références
J Biomol Struct Dyn. 2021 May;39(8):2857-2872
pubmed: 32295479
Indian J Pharmacol. 2020 Jan-Feb;52(1):56-65
pubmed: 32201449
Malays J Pathol. 2020 Apr;42(1):3-11
pubmed: 32342926
Lancet. 2021 Feb 20;397(10275):642-643
pubmed: 33545098
Vaccine. 2013 Jan 21;31(5):850-6
pubmed: 23123018
Nature. 2020 May;581(7807):221-224
pubmed: 32225175
Lancet. 2020 Aug 15;396(10249):479-488
pubmed: 32702299
J Med Virol. 2020 Apr;92(4):418-423
pubmed: 31967327
Nat Commun. 2020 Aug 14;11(1):4081
pubmed: 32796842
Vaccines (Basel). 2020 Jul 22;8(3):
pubmed: 32707833
Lancet. 2021 Feb 20;397(10275):643-645
pubmed: 33524312
Biomed J. 2020 Aug;43(4):328-333
pubmed: 32387617
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
Viruses. 2010 Aug;2(8):1804-20
pubmed: 21994708
Cell Death Differ. 2021 Feb;28(2):626-639
pubmed: 33479399
Virol J. 2019 May 27;16(1):69
pubmed: 31133031
Lancet Infect Dis. 2021 Jun;21(6):803-812
pubmed: 33548194
Theranostics. 2021 Jan 1;11(4):1690-1702
pubmed: 33408775
Lancet. 2020 Sep 26;396(10255):887-897
pubmed: 32896291
J Postgrad Med. 2016 Jan-Mar;62(1):4-11
pubmed: 26732191
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Nat Rev Drug Discov. 2018 Apr;17(4):261-279
pubmed: 29326426
Nature. 2020 Apr;580(7805):576-577
pubmed: 32346146
Ann Allergy Asthma Immunol. 2020 Jul;125(1):17-27
pubmed: 32044451
Adv Drug Deliv Rev. 2021 Mar;170:71-82
pubmed: 33421475
Nat Microbiol. 2020 Apr;5(4):536-544
pubmed: 32123347
BMJ. 2021 Jan 11;372:n74
pubmed: 33431500
Mayo Clin Proc. 2020 Oct;95(10):2172-2188
pubmed: 33012348
Vaccines (Basel). 2014 Jul 29;2(3):624-41
pubmed: 26344749
Signal Transduct Target Ther. 2020 Oct 13;5(1):237
pubmed: 33051445